title: New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.
abstract: A small subset of T cells (gamma-delta T cells) is able to recognize phosphoantigens that are overexpressed in some cancer cells and may selectively target and kill cancer cells with high levels of phosphoantigen. Moreover, nitrogen-containing bisphosphonates, such as zoledronic acid, are able to induce accumulation of specific phosphoantigens in some cancer cells. A recent preclinical study showed that gamma-delta T cells effectively targeted and killed zoledronic acid-treated estrogen-receptor-positive breast cancer cells. These new data provide growing insight into a potential mechanism of action for some of the anticancer activity demonstrated by zoledronic acid in breast cancer clinical trials.
authors.affiliation: Department of Medicine/Medical Oncology, Duke University Medical Center, Durham, NC, USA.
authors.forename: Erika
authors.initials: E
authors.lastname: Hamilton
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Clay
authors.forename: Kimberly L
authors.initials: KL
authors.lastname: Blackwell
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000502:physiology; D013601:T-Lymphocytes / Q000276:immunology; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D016692:Receptors, Antigen, T-Cell, gamma-delta; D000077211:Zoledronic Acid